source
- Valneva to cut up to 15% of jobs as reduced travel hits vaccine demandFrench vaccine maker Valneva is laying off 10% to 15% of its workforce and reducing revenue projections due to "an emerging adverse trend in travel vaccine uptake across key markets." The drugmakerEndpoints · 3mo ago↗ source
- FDA’s leadership void leaves biotech with renewed ‘uncertainty’Marty Makary's resignation leaves the agency with temporary directors in three top positions, and a number of newly instituted policies with an unclear future.BioPharma Dive · 3mo ago↗ source
- Abeona pivots to T cells; AstraZeneca's rare disease drug passes Phase 3Plus, news about Amicus Therapeutics, Fosun Pharma, Duality Biotherapeutics, BioNTech and C4 Therapeutics. 👁️ Abeona drops eye gene therapies, pivots to solid tumor T cell therapy: The biotech, wh…